[Osimertinib in lung cancer]
Gonzalez L, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A,
Record ID 32018001514
Spanish
Original Title:
Osimertinib en cáncer de pulmón
Authors' recommendations:
CONCLUSIONS
High-quality evidence shows that in patients with advanced lung cancer the use of osimertinib would increase progression-free survival and overall response rate as first-line therapy in patients with EGFR mutations. Similar results have been observed when used in patients with T790M mutation who have previously received erlotinib, gefitinib or afatinib. The impact of its use on overall survival was immature at the time two randomized clinical trials were published.
There is consensus among the clinical practice guidelines to recommend its use for these indications. The coverage policies of the consulted sponsors, all of them from developed countries, cover it for patients with T790M mutation who progressed to an EGFR inhibitor. At present, its coverage as first-line therapy is under evaluation in several countries. For the time being, only private sponsors from the United States cover it.
In Argentina, no cost-effectiveness or budget impact studies have been found. The economic evaluations found conclude that the use of osimertinib at the sale price and as first-line therapy in Brazil and the United States or as second-line therapy in Canada, Australia and the United Kingdom was not cost-effective. Consequently, some sponsors only consider its coverage after a price-reduction agreement in order to guarantee its cost-effectiveness in the local setting.
Details
Project Status:
Completed
Year Published:
2018
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Agents
- Protein Kinase Inhibitors
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.